French beauty giant L’Oréal announced on Monday, June 9, that it will acquire a majority stake in British skincare brand Medik8 for an undisclosed amount</strong>.
“L’Oréal Groupe today announced that it has signed an agreement to acquire a majority stake in the British skincare brand Medik8,” the French company announced in a press release.
The high-end brand will join the L’Oréal Luxe division, with strong global growth potential — particularly in the U.S. — following the completion of the transaction, expected in the coming months, the group stated.
Medik8’s main shareholder since 2021, the investment fund Inflexion, which supported the brand in the launch of a new research center and its development in the United States, will retain a minority stake. However, L’Oréal said it has secured “rights to buyout in full the minority shareholders.”
Medik8’s founder will continue to serve on the board, with the current management committee also remaining in place “to ensure continuity,” added the French group.
Founded in 2009 by scientist Elliot Isaacs, Medik8 employs more than 300 staffs and boasts a range of products made in the UK. The company recorded net sales of GBP 45.3 million (around EUR 53.8 million or USD 61,5 at current exchange rates) in its financial year ending September 2023, according to accounts filed with the British Companies Register and seen by AFP.
Last week, the Financial Times reported that the deal was valued at one billion euros.
“As a premium skincare range, with high levels of proven efficacy at an accessible price point, Medik8 perfectly complements our existing skincare portfolio,” explained Cyril Chapuy, President of L’Oréal Luxe.
In 2023, L’Oréal acquired the Australian luxury cosmetics brand Aesop, then valued at USD 2.5 billion.
The following year, the French group — owner of brands such as Garnier, Maybelline, and L’Oréal Paris —strengthened its presence in the high-end segment through a partnership with Italian luxury group Prada around the Miu Miu brand, and by increasing its stake in the Swiss laboratory Galderma.
In the first quarter of 2025, L’Oréal posted a 4.4% increase in sales to EUR 11.7 billion. By category, its luxury division (Lancôme, Yves Saint Laurent, Armani, Kiehl’s, etc.) remains the most dynamic, with growth of 7.3% to EUR 4.1 billion.
Portfolio
